CHICAGO, May 1, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 8 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results.
The conference call will be available via phone and webcast. To access the call, please dial 866-632-4021 for participants in the U.S. or Canada and 404-991-3968 for international callers (reference Conference ID 34955177). A replay of the call may be accessed through May 22, 2014 by dialing 800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for international callers (reference Conference ID 34955177). The conference call will also be webcast live on the Investor Relations section of the Company's website at www.duratatx.com.
About Durata Therapeutics, Inc.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
CONTACT: Investor Relations and Public Affairs Contact Allison Wey Durata Therapeutics Vice President, Investor Relations and Public Affairs (312) 219-7017 firstname.lastname@example.org Media Relations Contact Geoff Curtis DJE Science (312) 233-1253 email@example.com
Source:Durata Therapeutics, Inc.